Poolbeg Pharma (LON:POLB) Trading 13.3% Higher – Time to Buy?

Poolbeg Pharma PLC (LON:POLB)’s share price shot up 13.3% on Tuesday . The company traded as high as GBX 4.70 and last traded at GBX 4.70. 812,935 shares traded hands during trading, a decline of 37% from the average session volume of 1,294,316 shares. The stock had previously closed at GBX 4.15.

Analysts Set New Price Targets

Separately, Shore Capital Group reissued a “house stock” rating on shares of Poolbeg Pharma in a research report on Wednesday, January 28th.

Poolbeg Pharma Trading Up 13.3%

The company has a market cap of £33.14 million, a price-to-earnings ratio of -4.12 and a beta of 2.00. The firm’s 50-day moving average price is GBX 4.39 and its 200 day moving average price is GBX 4.07.

About Poolbeg Pharma

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.